Actively Recruiting
ALDH2 Single Nucleotide Polymorphisms and Prognosis of Esophageal Cancer Patients
Led by National Taiwan University Hospital · Updated on 2026-01-07
700
Participants Needed
1
Research Sites
98 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Alcohol consumption, smoking, and betel nut chewing have been proven to be closely associated with the risk of esophageal cancer (EC). Recent studies have shown that alcohol-related detoxification genes in the ALDH family influence individual susceptibility to esophageal cancer. Aldehyde dehydrogenase 2 (ALDH2) is one of the most important enzymes in the ALDH family, involved in the metabolism of alcohol, acetaldehyde, and environmental aldehydes in the human body. We hypothesize that functional variations in ALDH2 may have a significant impact on the survival of esophageal cancer patients. This study aims to investigate the correlation between ALDH2 gene polymorphism and the survival of esophageal cancer patients.
CONDITIONS
Official Title
ALDH2 Single Nucleotide Polymorphisms and Prognosis of Esophageal Cancer Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients who have been pathologically confirmed to have esophageal cancer
- Patients who have signed consent forms to provide remaining samples for research
You will not qualify if you...
- Female patients
- Patients younger than 18 years old
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
National Taiwan University Hospital
Taipei, Taiwan
Actively Recruiting
Research Team
J
Jang-Ming Lee
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here